Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
PLANO, Texas, Nov. 02, 2016 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the third quarter ended September 30, 2016 on Wednesday, November 9, 2016 after the market close.
Nuvectra will hold a conference call on Wednesday, November 9, 2016 at 4:30pm ET to discuss the results. The dial in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international callers. The conference ID is 94246838. A live webcast of the conference call will be available on the investor relations section of the Company’s website at http://investors.nuvectramed.com/.
A replay of the call will be available starting on November 9, 2016 through November 16, 2016. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and enter access code 94246838. The webcast will be available in the investor relations section of the Company’s website for 90 days following the completion of the call.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
